Merck KGaA's BTK inhibitor hit by partial clinical hold over safety concern, but PhIII readout unaffected
The FDA has slapped a partial clinical hold on Merck KGaA’s evobrutinib due to worries about liver injury arising from its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
